| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB400-113SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB500-205 | |||
| BSA Free | NB500-205SS | |||
| BSA Free | NB500-238SS | |||
| Azide and BSA Free | NBP2-80969 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-48309SS | |||
| Azide and BSA Free | NBP2-80868 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-05198-0.025ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-76769SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-202SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-615SS | |||
| Azide and BSA Free | NBP2-80617 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB100-55744 | |||
| BSA Free | NB100-56618SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-27103SS | |||
| Azide and BSA Free | NBP2-80749 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-89062SS | |||
| Azide and BSA Free | NBP2-80895 | |||
![Western Blot: SR-BI Antibody [NB400-113] - Detection of SR-BI (80kDa) in mouse testis lysate total protein using NB400-113.](http://images.novusbio.com/fullsize/SR-BI-Antibody-Western-Blot-NB400-113-img0009.jpg "Western Blot: SR-BI Antibody [NB400-113] - Detection of SR-BI (80kDa) in mouse testis lysate total protein using NB400-113.")
![Immunocytochemistry/Immunofluorescence: SR-BI Antibody [NB400-113] - Antibody was tested in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/SR-BI-Antibody-Immunocytochemistry-Immunofluorescence-NB400-113-img0006.jpg)
![Immunohistochemistry-Paraffin: SR-BI Antibody [NB400-113] - Analysis of a FFPE section of human adrenal gland tissue using 1:100 dilution of SR-BI antibody. The staining was developed using HRP-DAB based detection method and the nuclei of the cells were counterstained with hematoxylin. This antibody generated a specific staining of SR-BI/SCARB1 in the glandular cells. The staining was membrane-cytoplasmic in the zona glomerulosa cells while the signal was primarily localized to the membranes of the cells in the zona fasciculata and zona reticularis layers of the adrenal cortex.](http://images.novusbio.com/fullsize/SR-BI-Antibody-Immunohistochemistry-Paraffin-NB400-113-img0008.jpg)
![Immunohistochemistry-Paraffin: SR-BI Antibody [NB400-113] - Analysis of a FFPE section of human adrenal gland tissue using 1:100 dilution of SR-BI antibody. The staining was developed using HRP-DAB based detection method and the nuclei of the cells were counterstained using hematoxylin. The representative section shows SR-BI/SCARB1 positivity in the glandular cells and the staining was mainly localized to the membranes of the cells.](http://images.novusbio.com/fullsize/SR-BI-Antibody-Immunohistochemistry-Paraffin-NB400-113-img0007.jpg)
![Western Blot: SR-BI Antibody [NB400-113] - Cell surface expression of SR-BI in renal carcinoma cells. Western blot analysis of SR-BI in total cell lysates (left) and on the cell surface (right) in 786-O and 786-O-VHL cells. The Western blots were probed with anti-SR-BI (82 kDa), anti-TBP (40 kDa, used as a control for intracellular protein expression), and anti-Na+/K+-ATPase (110 kDa, used as a control for cell surface protein expression). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30173145/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nb400-113_rabbit-polyclonal-sr-bi-antibody-2552023151494.jpg)
![Immunohistochemistry: Survivin Antibody (60.11) [NB500-238] - Low-power image of human high-grade chondrosarcoma displays strong cellular expression of survivin protein (A). High-power magnification reveals the predominantly cytoplasmic staining, although strong nuclear signals are detectable (B). Other specimen of a grade III chondrosarcoma stained with monoclonal antibody, shows a similar pattern of staining (C and D). For A and B the polyclonal rabbit anti-survivin antibody [AF886] was used. For C and D the monoclonal mouse Survivin Antibody (60.11) [NB500-238] was used. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-120), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Survivin-Antibody-60-11-Immunohistochemistry-NB500-238-img0019.jpg "<b>Independent Antibodies Validation. </b>Immunohistochemistry: Survivin Antibody (60.11) [NB500-238] - Low-power image of human high-grade chondrosarcoma displays strong cellular expression of survivin protein (A). High-power magnification reveals the predominantly cytoplasmic staining, although strong nuclear signals are detectable (B). Other specimen of a grade III chondrosarcoma stained with monoclonal antibody, shows a similar pattern of staining (C and D). For A and B the polyclonal rabbit anti-survivin antibody [AF886] was used. For C and D the monoclonal mouse Survivin Antibody (60.11) [NB500-238] was used. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-120), licensed under a CC-BY license.")
![<b>Independent Antibodies Validation. </b>Flow (Intracellular): Survivin Antibody (60.11) [NB500-238] - An intracellular stain was performed on A549 cells with Survivin Antibody (60.11) [NB500-238] and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems). Image using the Unpurified form of this antibody.](http://images.novusbio.com/fullsize/Survivin-Antibody-60-11-Flow-Intracellular-NB500-238-img0015.jpg)
![Western Blot: Survivin Antibody (60.11) [NB500-238] - Survivin detection in 30ug of HeLa whole cell extract using [NB500-238] at 1ug/ml. Detected at predicted molecular weight of 16 kDa.](http://images.novusbio.com/fullsize/Survivin-Antibody-60-11-Western-Blot-NB500-238-img0006.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: Survivin Antibody (60.11) [NB500-238] - Knockdown Validation of Survivin Antibody (60.11) [NB500-238]. Suppression of survivin expression by transfection of siRNA. RNA interference was performed in SW1353 and Hs 819.T, either for GFP as control or for survivin. A: A pronounced decrease of survivin protein levels was measured by immunoblotting in SW1353 and Hs819.T. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-120), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Survivin-Antibody-60-11-Knockdown-Validated-NB500-238-img0020.jpg)
![Immunocytochemistry/Immunofluorescence: Survivin Antibody (60.11) [NB500-238] - HeLa cells stained NB500-205 (Green) detected with DyLight Fluor 488 conjugated anti-mouse IgG secondary antibody. Nuclei are counterstained with Hoechst 33258 (Blue). Image using the Unpurified format of this antibody.](http://images.novusbio.com/fullsize/Survivin-Antibody-60-11-Immunocytochemistry-Immunofluorescence-NB500-238-img0021.jpg)
![Immunohistochemistry-Paraffin: Survivin Antibody (60.11) [NB500-238] - Staining of ovary cancer. Image using the Unpurified format of this antibody.](http://images.novusbio.com/fullsize/Survivin-Antibody-60-11-Immunohistochemistry-Paraffin-NB500-238-img0022.jpg)
![Flow Cytometry: Survivin Antibody (60.11) [NB500-238] - An intracellular stain was performed on U2OS cells with Survivin Antibody (60.11) [NB500-238AF700] (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/Survivin-Antibody-60-11-Flow-Cytometry-NB500-238-img0017.jpg)
![Flow (Intracellular): Survivin Antibody (60.11) [NB500-238] - An intracellular stain was performed on Daudi cells with Survivin Antibody (60.11)[NB500-238] (blue) and a matched isotype control, Mouse IgG2a Kappa Light Chain Isotype Control (MG2a-53) [NB600-986] (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).](http://images.novusbio.com/fullsize/Survivin-Antibody-60-11-Flow-Intracellular-NB500-238-img0014.jpg)
![Western Blot: Survivin Antibody (60.11) - BSA Free [NB500-238] - Binding of antibody (60.11) used in imaging flow cytometry to full-length survivin protein & to survivin vaccine peptide aa53-67/M57 & wild type peptide aa53-67 Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.21773), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-238_mouse-monoclonal-survivin-antibody-60-11-31020241539726.jpg)
![Western Blot: Survivin Antibody (60.11) - BSA Free [NB500-238] - CD133+ cells are more resistant to chemotherapeutic agents. STA-ET-8.2 cells were FACS-sorted & CD133+ & CD133- fractions treated with increasing concentrations of (A) Doxorubicin (Doxo), (B) Etoposide (Etop), (C) Vincristine (Vinc) or (D) a combination of all three drugs at high (Doxo 10 μM; Etop 10 ug/ml; Vinc 100 ng/ml), medium (Doxo 2.5 μM; 20 Etop 2.5 ug/ml; Vinc 25 ng/ml) & low (Doxo 0.5 μM; Etop 0.5 ug/ml; Vinc5 ng/ml) concentrations. Viability was assessed by MTS assay after 96 hrs (*p < 0.05) & CD133+ cells displayed increased drug resistance. (E): CD133+ & CD133- TC-71 cells are equally sensitive to Doxo, Etop, & Vinc. (F): Western blot reveals no difference in apoptosis & drug resistance protein expression between unsorted & CD133-sorted STA-ET-8.2 cell fractions. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/20346143), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-238_mouse-monoclonal-survivin-antibody-60-11-310202416163762.jpg)
![Immunocytochemistry: N-Cadherin Antibody (13A9) [NBP1-48309] - Immunostaining of original tumor, low passage, and high passage KCI-MENG1 cells. The original patient-derived tumor (top row) showed moderate and patchy immunoreactivity for epithelial membrane antigen (EMA); strong and diffuse immunostaining for progesterone receptor (PR); and a Ki-67 proliferative index of 2-3%. There was also strong immunostaining for N-cadherin and vimentin. KCI-MENG1-LP cells (middle row) and KCI-MENG1-HP cells (bottom row) maintained expression of EMA, N-cadherin, and vimentin but had significantly reduced PR expression compared to the original tumor. Whereas Ki-67 labeling was found in only a small number of cells in the original tumor and low passage cells, it was positive in virtually all P84 cells. Scale bar 50 um. Image collected and cropped by CiteAb from the following publication (//www.translational-medicine.com/content/13/1/227), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/N-Cadherin-Antibody-13A9-Immunocytochemistry-NBP1-48309-img0025.jpg "Immunocytochemistry: N-Cadherin Antibody (13A9) [NBP1-48309] - Immunostaining of original tumor, low passage, and high passage KCI-MENG1 cells. The original patient-derived tumor (top row) showed moderate and patchy immunoreactivity for epithelial membrane antigen (EMA); strong and diffuse immunostaining for progesterone receptor (PR); and a Ki-67 proliferative index of 2-3%. There was also strong immunostaining for N-cadherin and vimentin. KCI-MENG1-LP cells (middle row) and KCI-MENG1-HP cells (bottom row) maintained expression of EMA, N-cadherin, and vimentin but had significantly reduced PR expression compared to the original tumor. Whereas Ki-67 labeling was found in only a small number of cells in the original tumor and low passage cells, it was positive in virtually all P84 cells. Scale bar 50 um. Image collected and cropped by CiteAb from the following publication (//www.translational-medicine.com/content/13/1/227), licensed under a CC-BY license.")
![Western Blot: N-Cadherin Antibody (13A9) [NBP1-48309] - Western blots showing a reduction in epithelial mesenchymal transition (EMT) markers upon PDK1 knockdown in Colo205 and HT29 cells using E cadherin (NBP2-19051), N cadherin (NBP1-48309) and B-actin antibody (NB600-501). The corresponding secondary antibodies used were either goat anti-rabbit IgG-HRP (NB7160) or goat anti-mouse IgG-HRP (NB7539). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33738242) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/N-Cadherin-Antibody-13A9-Western-Blot-NBP1-48309-img0029.jpg)
![Western Blot: N-Cadherin Antibody (13A9) [NBP1-48309] - Analysis of N-Cadherin expression in HeLa whole cell lysate.](http://images.novusbio.com/fullsize/N-Cadherin-Antibody-13A9-Western-Blot-NBP1-48309-img0005.jpg)
![Immunocytochemistry: N-Cadherin Antibody (13A9) [NBP1-48309] - Human meningioma mouse xenograft model KCI-MENG1-LPSX generated with the spontaneously immortal cell line KCI-MENG1-LP. Tumors from immunocompromised SCID mice were dissected and the derivative cell line KCI-MENG1-LPSX CL was generated. The EMA, PR, and N-cadherin IHC of the mouse tumor highly resembled the original patient-derived tumor. The vimentin- and Ki-67-stained cells in the mouse tumor tissue were markedly more abundant and more intensely stained than in the original tumor. KCI-MENG1-LPSX CL cells displayed the same patterns of immunostaining as the high passage parent cell line KCI-MENG1-HP, including the loss of PR staining. Scale bar 50 um. Image collected and cropped by CiteAb from the following publication (//www.translational-medicine.com/content/13/1/227), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/N-Cadherin-Antibody-13A9-Immunocytochemistry-NBP1-48309-img0026.jpg)
![Flow (Intracellular): N-Cadherin Antibody (13A9) [NBP1-48309] - An intracellular stain was performed on HeLa with NBP1-48309 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Mouse F(ab)2 IgG (H+L) PE-conjugated Antibody.](http://images.novusbio.com/fullsize/N-Cadherin-Antibody-13A9-Flow-Intracellular-NBP1-48309-img0010.jpg)
![Simple Western: N-Cadherin Antibody (13A9) [NBP1-48309] - Simple Western lane view shows a specific band for N Cadherin in 1.0 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/N-Cadherin-Antibody-13A9-Simple-Western-NBP1-48309-img0008.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: N-Cadherin Antibody (13A9) [NBP1-48309] - Mitochondrial fission regulates migration and invasion in BRAF^V600E CRC cells through glucose metabolic reprograming. Western blot showing a reduction in EMT markers upon vemurafenib treatment in BRAF^V600E cells. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33738242/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/N-Cadherin-Antibody-13A9-Western-Blot-NBP1-48309-img0032.jpg)
![Immunocytochemistry/Immunofluorescence: N-Cadherin Antibody (13A9) [NBP1-48309] - Adult mouse neural stem cells stained for N-Cadherin. Antibody at 1:100. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/N-Cadherin-Antibody-13A9-Immunocytochemistry-Immunofluorescence-NBP1-48309-img0027.jpg)
![Immunohistochemistry: N-Cadherin Antibody (13A9) [NBP1-48309] - Immunohistochemical characterization of tissue cultures. Nuclei labeled with DAPI (blue). Whole-mount immunostaining of a cardiomyocyte-only spheroid 1 month in culture, N-cadherin (red) and EH-myomesin (green). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32118040/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/N-Cadherin-Antibody-13A9-Immunohistochemistry-NBP1-48309-img0031.jpg)
![Flow Cytometry: N-Cadherin Antibody (13A9) [NBP1-48309] - An intracellular stain was performed on U-251 MG cells with N-Cadherin Antibody (13A9) NBP1-48309AF594 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 594.](http://images.novusbio.com/fullsize/N-Cadherin-Antibody-13A9-Flow-Cytometry-NBP1-48309-img0030.jpg)
![Immunocytochemistry/Immunofluorescence: N-Cadherin Antibody (13A9) [NBP1-48309] - HEK 293 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. The cells were incubated with anti- at 5 ug/mL overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/N-Cadherin-Antibody-13A9-Immunocytochemistry-Immunofluorescence-NBP1-48309-img0021.jpg)
![Immunohistochemistry: N-Cadherin Antibody (13A9) [NBP1-48309] - IHC analysis of N Cadherin in mouse liver using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/N-Cadherin-Antibody-13A9-Immunohistochemistry-NBP1-48309-img0007.jpg)
![Immunohistochemistry-Paraffin: N-Cadherin Antibody (13A9) [NBP1-48309] - Analysis of a FFPE tissue section of human brain using 1:200 dilution of N-Cadherin antibody. The staining was developed using HRP labeled anti-mouse secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/N-Cadherin-Antibody-13A9-Immunohistochemistry-Paraffin-NBP1-48309-img0028.jpg)
![Flow Cytometry: N-Cadherin Antibody (13A9) [NBP1-48309] - An intracellular stain was performed on HeLa cells with NBP1-48309AF488 and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/N-Cadherin-Antibody-13A9-Flow-Cytometry-NBP1-48309-img0016.jpg)
![Immunohistochemistry Free-Floating: GFAP Antibody [NBP1-05198] - Staining of a section of mouse hippocampus stained with chicken pAb to GFAP, NBP1-05198, dilution 1:5000 in green and costained with rabbit pAb to FOX3/NeuN, dilution 1:5000, in red. The blue is DAPI staining of nuclear DNA. Following transcardial perfusion with 4% paraformaldehyde, mouse brain was post fixed for 24 hours, cut to 45 uM, and free-floating sections were stained with the above antibodies. The GFAP antibody stains a network of astroglial cells while the Fox3/NeuN antibody stains the nuclei and proximal perikarya of neurons.](http://images.novusbio.com/fullsize/GFAP-Antibody-NBP1-05198-img0001.jpg "Immunohistochemistry Free-Floating: GFAP Antibody [NBP1-05198] - Staining of a section of mouse hippocampus stained with chicken pAb to GFAP, NBP1-05198, dilution 1:5000 in green and costained with rabbit pAb to FOX3/NeuN, dilution 1:5000, in red. The blue is DAPI staining of nuclear DNA. Following transcardial perfusion with 4% paraformaldehyde, mouse brain was post fixed for 24 hours, cut to 45 uM, and free-floating sections were stained with the above antibodies. The GFAP antibody stains a network of astroglial cells while the Fox3/NeuN antibody stains the nuclei and proximal perikarya of neurons.")
![Western Blot: GFAP Antibody [NBP1-05198] - Analysis of whole brain lysates using chicken pAb to GFAP, NBP1-05198, dilution 1:5000 in green: [1] protein standard (red), [2] rat brain, [3] mouse brain. The strong band at about 50 kDa corresponds to the GFAP protein. Smaller proteolytic fragments and alternate transcripts of GFAP may also be detected on such blots.](http://images.novusbio.com/fullsize/GFAP-Antibody-NBP1-05198-img0002.jpg)
![Simple Western: GAPDH Antibody [NB300-322] - Simple Western lane view shows a specific band for GAPDH in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. Note: band observed higher than predicted molecular weight of 36 kDa.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Simple-Western-NB300-322-img0005.jpg "Simple Western: GAPDH Antibody [NB300-322] - Simple Western lane view shows a specific band for GAPDH in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. Note: band observed higher than predicted molecular weight of 36 kDa.")
![Western Blot: GAPDH Antibody [NB300-322] - Detection of Human and Mouse GAPDH (theoretical molecular weight: 36 kDa) by Western Blot. Samples: Whole cell lysate (15 ug) from HeLa, 293T, Jurkat, mouse TCMK-1, and mouse NIH3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-GAPDH antibody NB300-322 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Western-Blot-NB300-322-img0007.jpg)
![Western Blot: GAPDH Antibody [NB300-322] - Detection of Human and Mouse GAPDH (theoretical molecular weight: 36 kDa) by Western Blot. Samples: Whole cell lysate from mouse NIH3T3 (5, 15 and 50 ug) and human HeLa (H; 50 ug) cells. Antibody: Affinity purified rabbit anti-GAPDH antibody used at 0.04 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Western-Blot-NB300-322-img0006.jpg)
![Immunohistochemistry: GAPDH Antibody [NB300-322] - Detection of human GAPDH by immunohistochemistry. Sample: FFPE section of human colon carcinoma. Antibody: Affinity purified rabbit anti-GAPDH (NB300-322). Detection: DAB](http://images.novusbio.com/fullsize/GAPDH-Antibody-Immunohistochemistry-NB300-322-img0008.jpg)
![Western Blot: GAPDH Antibody [NB300-322] - c-Src is required for efficient translation of PRC2 component mRNAs. Immunoblot of PRC2 components in control and c-Src-deficient tumors. Bar chart shows quantification of fluorescent immunoblot data normalized to the loading control (Gapdh). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-019-10681-4), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Western-Blot-NB300-322-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: GAPDH Antibody [NB300-322] - GAPDH detection in HeLa cells with ICC-IF application using NB300-322, visualized with DyLight Fluor 488.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Immunocytochemistry-Immunofluorescence-NB300-322-img0003.jpg)
![Immunohistochemistry: GAPDH Antibody [NB300-322] - Detection of mouse GAPDH by immunohistochemistry. Sample: FFPE section of mouse plasmacytoma. Antibody: Affinity purified rabbit anti-GAPDH (NB300-322). Detection: DAB](http://images.novusbio.com/fullsize/GAPDH-Antibody-Immunohistochemistry-NB300-322-img0009.jpg)
![Western Blot: GAPDH Antibody [NB300-322] - Mouse DRG stained at 1:2000 dilution. Image provided by verified customer review.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Western-Blot-NB300-322-img0004.jpg)
![Western Blot: GAPDH Antibody [NB300-322] - Gem expression is sufficient to increase chemokinesis and chemotaxis. Western blot analyses were performed on 70 ug of cellular extracts from MOLT4 cells transduced by Lenti-control or Lenti-GEM viral particles. Membranes were probed with anti-Gem (1:2,000) or anti-GAPDH (1:1,000) antibody. ***: significantly different, p 0.1), Fgenotype(1,30) = 30.7 (p Int J Mol Sci (2024). Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-322_rabbit-polyclonal-gapdh-antibody-12220251513483.jpg)
![Simple Western: GAPDH Antibody [NB300-322] - Astroglial expression in the plasma membrane evoked by ripple burst and fast ripple burst stimulations in wild type and S286L-TG. Panel (A) indicates expression of pannexin1 in the astroglial plasma membrane fraction. Ordinates indicate the mean ± SD (n = 6) of relative expression of pannexin1 per GAPDH. Gray and green bars indicate pannexin1 expression in astrocytes of wild type and S286L-TG after chronic fast ripple-evoked stimulation, respectively. * p 0.1), Fgenotype*age(1,20) = 5.4 (p Int J Mol Sci (2024). Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-322_rabbit-polyclonal-gapdh-antibody-12220251513482.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - Validation with PD-L1 siRNA Knockdown. HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2). Loading: 10 ug of HeLa whole cell lysates per lane. Antibodies: NBP1-76769 (2 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Knockdown-Validated-NBP1-76769-img0024.jpg "<b>Genetic Strategies Validation. </b>Western Blot: PD-L1 Antibody [NBP1-76769] - Validation with PD-L1 siRNA Knockdown. HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2). Loading: 10 ug of HeLa whole cell lysates per lane. Antibodies: NBP1-76769 (2 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.")
![<b>Independent Antibodies Validation and Genetic Strategies Validation.</b>Western Blot: PD-L1 Antibody [NBP1-76769] - Independent Antibody Validation (IAV) via Protein Expression ProfileLoading: 15 ug of lysates per lane.Antibodies: NBP1-76769 (2 ug/mL), PD-L1 (2 ug/mL), and beta-actin (1 ug/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit and or anti-mouse IgG HRP conjugate at 1:10000 and 1:5000 dilution, respectively.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0023.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - CD274 (PD-L1) expression in the HNSCC patients from the TCGA database , HNSCC tissue samples and the HNSCC cells. Immunostaining of PD-L1 obtained from HNSCC tumor cells, immune cells and tumor margin tissues in HNSCC tissue samples (magnification A-200, scale bars 50AI1/4m) : low tumor staining; moderate tumor staining; high tumor staining have been observed. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-Negative-NBP1-76769-img0025.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - PD-L1 expression was evaluated in gastric cancer cells. Levels of PD-L1 protein were assessed in normal human gastric epithelial cells and 8 gastric cancer cell lines by Western blots. Image collected and cropped by Citeab from the following publication (Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Cancer Res (2019)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0026.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: PD-L1 Antibody [NBP1-76769] - Upregulated expression of PD-L1 in cisplatin-resistant cells through IL-6/STAT3. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0027.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - CD274 (PD-L1) expression in the HNSCC patients from the TCGA databas HNSCC cells. CD274 expression with survival and its relation with therapy in the HNSCC patients from the TCGA database. Expression of CD274 gene and PD-L1 protein in the established cisplatin-resistant HNSCC cells and cisplatin sensitive cells by qRT-PCR and WB (F, H): CD274 (PD-L1) expressed in cisplatin resistant cell. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0028.jpg)
![Immunocytochemistry/Immunofluorescence: PD-L1 Antibody [NBP1-76769] - U-251 MG cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP1-76769 at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-76769-img0029.jpg)
![Flow Cytometry: PD-L1 Antibody [NBP1-76769] - An intracellular stain was performed on U-251 MG cells with PD-L1 Antibody NBP1-76769 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NBP1-76769-img0030.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - Expression of CD274 in Human melanoma SK-MEL-28 cell line upon treatment with 200 mM ethanol. Dilution: 1:1,000 in PBS with 5% BSA. Secondary Ab: anti-Rabbit IgG 1:5,000. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0019.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Human tonsil tissue with PD-L1 antibody at 5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0017.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - Staining of human heart tissue with antibody at 2.5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0010.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - PD-L1/B7-H1 Antibody [NBP1-76769] - PD-L1 in rat heart tissue with at 5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0020.jpg)
![Flow Cytometry: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Analysis of A-20 cells using B7-H1/PD-L1/CD274 antibody at 0.5 ug/mL. Green: Isotype control. Red : B7-H1/PD-L1/CD274 antibody.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NBP1-76769-img0018.jpg)
![Immunofluorescence: PD-L1 Antibody [NBP1-76769] - Human Heart cells with PD-L1 antibody at 20 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunofluorescence-NBP1-76769-img0009.jpg)
![Dual RNAscope ISH-IHC: PD-L1 Antibody [NBP1-76769] - PDCD1 mRNA (red) and PD-L1 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human lung cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-PDCD1 and PD-L1 antibody at 1:100 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Dual-RNAscope-ISH-IHC-NBP1-76769-img0031.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ROS mediated PD-L1 upregulation in FFA-treated LO2 cells. (a) Intracellular ROS in LO2 cells before & after FFA treatment measured by DCFH-DA. (b–d) Expression levels of NOX2 & NOX4 measured using qRT-PCR & western blot. (e) JC-1 probes were used to detect mitochondrial membrane potential. (f–j) Intracellular ROS in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment, measured by DCFH-DA, PD-L1 expression determined by western blot. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415382415.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-31020241534538.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 expression levels in liver samples & FFA-treated LO2 cells. (a–d) PD-L1 expression & CD8+ T cells in the liver tissues determined by immunohistochemistry. (e) Intracellular lipid accumulation after FFA treatment (0.8 mM) for 24 hour measured by Oil Red staining. (f–i) Expression levels of PD-L1 detected by qRT-PCR, western blot, & immunofluorescence. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415175299.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415291978.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415175210.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ROS/ZNF24/PD-L1 pathway activation in NAFLD models. (a) Intracellular ROS in hepatocytes in NAFLD significantly increased. (b) JC-1 probes were used to detect mitochondrial membrane potential. (c & d) NOX4 & ZNF24 expressions were determined by immunohistochemistry. (e & f) ROS/ZNF24/PD-L1 pathway activation examined by western blot. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415284517.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 limits liver injury in NAFLD models. (a & b) Western blot determined the effect of siRNA against PD-L1. (c) After PD-L1 knockdown, mRNA expression levels of markers of T cell activation measured by qRT-PCR. (d & e) Hepatocyte injury was evaluated by the Tunel assay & ALT/AST measurement. (f) Graph illustrating that both ROS/ZNF24 pathway activation & UBE2I-mediated ZNF24 sumoylation suppression induced by FFA promoted PD-L1 expression. ∗P < 0.05, ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-31020241529331.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 knockdown aggravated the damage of CD8 + T cells to FFA-treated LO2 cells. (a & b) Western blot determined the effect of siRNA against PD-L1. Coculturing of FFA-treated LO2 cells & CD8 + T cells in vitro. (c) mRNA expression levels of markers of T cell activation measured by qRT-PCR, (d) LO2 cell injury was evaluated by LDH assay, (e) AST or ALT in the supernatants measured by commercial assay kits. # represents that CD8 + T cells were incubated separately with LO2 cells, but supernatants were put together. ∗P < 0.05, ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415304228.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Upregulated expression of PD‐L1 in cisplatin‐resistant cells through IL‐6/STAT3. The cisplatin resistant CAL27cis & Detroit‐562cis cells had increased IL‐6 mRNA & IL‐6 protein production compared to parental cells by qRT‐PCR & ELISA (A, B). CAL27cis & Detroit‐562cis were cultured with IL‐6 (10 ng/mL, human recombinant IL‐6, R&D Systems, Minneapolis, USA) for 48 h (C). An anti‐human IL‐6 polyclonal antibody (R&D Systems, Minneapolis, USA) was used to neutralize the biological activities of IL‐6 (E, F). To inhibit signal transduction, CAL27cis & Detroit‐562cis cells were pre‐incubated for 1 h with STAT3 inhibitor V (Sigma‐Aldrich, Germany, 500 nmol/L), & then incubated with recombinant human IL‐6 (10 ng/mL) for 24 h before analysis. Data are shown as mean ± SD of 3 independent triplicate cultures (A, B, D, E, F, H). *P < .05, **P < .01 & ***P < .001, compared with the results of control without IL‐6 (D), control IgG (E, F) & with IL‐6 alone (H) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29761938), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175266.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ZNF24 promoted PD-L1 expression through binding to its promoter in FFA-treated LO2 cells. (a) A schematic of the target sites (wild & mutant) of ZNF24 in the promoter of PD-L1. (b–d) Dual-luciferase reporter assays performed in LO2 cells transfected with WT or MT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression. (e–g) ZNF24 expression after FFA treatment determined by qRT-PCR & western blot. (h & i) ZNF24 expression in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment, measured by western blot. (j & k) ZNF24 & PD-L1 expression in LO2 cells pretreated with siRNA against ZNF24, followed by FFA treatment detected by western blot. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416165623.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - LfcinB reduced IL‐6‐dependent PD‐L1 expression in cisplatin‐resistant HNSCC cells (A‐C) & inhibited the xenograft growth from CAL27cis & Detroit‐562cis (D, E). The markedly decreased IL‐6 (A) by ELISA & PD‐L1 by WB (B, C) in the acquired cisplatin‐resistant cells were detected. In figure A, C & D, data are shown as mean ± SD of 3 independent triplicate cultures. *P < .05 & **P < .01, compared with the results of control without IL‐6 (A, C). To investigate the effects of LfcinB on in vivo growth of CAL27cis & Detroit‐562cis, we treated nude mice carrying CAL27cis (D) & Detroit‐562cis (E) xenografts with once‐daily injection of 0.75 mg LfcinB (n = 5). Tumor growth of HNSCC xenografts displayed significant reduction after 3 days of LfcinB treatment, compared to control with saline (*P < .05 for LfcinB) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29761938), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175227.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Identification of ZNF24–UBE2I protein interactions. (a & b) Analysis of protein interactions between ZNF24 & UBE2I using the BioGRID database, further confirmed by Co-IP assays. (c–f) UBE2I expression in LO2 cells treated by FFA or pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment measured by western blot. (g & h) After FFA treatment, Sumo-1: ZNF24 & ZNF24 expression levels detected by western blot. (i & j) After UBE2I overexpression, Sumo-1: ZNF24, ZNF24, PD-L1, & UBE2I expression levels were determined by western blot. (k–m) Dual-luciferase reporter assays performed in LO2 cells transfected with WT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression with or without Sumo-1 overexpression. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175269.jpg)
![Western Blot: STEP Antibody (23E5) [NB300-202] - Analysis of STEP protein in striatal rat protein homogenates](http://images.novusbio.com/fullsize/STEP-Antibody-23E5-Western-Blot-NB300-202-img0002.jpg "Western Blot: STEP Antibody (23E5) [NB300-202] - Analysis of STEP protein in striatal rat protein homogenates")
![Immunohistochemistry-Paraffin: STEP Antibody (23E5) [NB300-202] - STEP was detected in immersion fixed paraffin-embedded sections of human brain basal ganglia using Mouse Anti-Human STEP (23E5) Monoclonal Antibody (Catalog # NB300-202) at 1:100 for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm in neurons.](http://images.novusbio.com/fullsize/STEP-Antibody-23E5-Immunohistochemistry-Paraffin-NB300-202-img0003.jpg)
![Western Blot: Caveolin-1 Antibody (7C8) [NB100-615] - Detection of caveolin in 3T3 cell lysates (50 ug). Lanes 1 and 2: 1:4000. Lanes 3 and 4: 1:1000. Detection by ECL: 5 minute exposure.](http://images.novusbio.com/fullsize/Caveolin-1-Antibody-7C8-Western-Blot-NB100-615-img0010.jpg "Western Blot: Caveolin-1 Antibody (7C8) [NB100-615] - Detection of caveolin in 3T3 cell lysates (50 ug). Lanes 1 and 2: 1:4000. Lanes 3 and 4: 1:1000. Detection by ECL: 5 minute exposure.")
![Immunocytochemistry/Immunofluorescence: Caveolin-1 Antibody (7C8) [NB100-615] - Subcellular localization of mPARM-1 and hPARM-1 (full-length and mutant proteins). NIH/3T3 cells transiently expressing hPARM-1-GFP or deltaCT-GFP were fixed, immunostained for caveolin-1 (1:100, Novus Biologicals), and examined by confocal fluorescence microscopy. For hPARM-1-GFP-caveolin-1 co-localization, cells that demonstrated cell membrane PARM-1 localization were chosen. All co-localizations were observed following merging images of GFP-tagged proteins with those of Golgi, endosomes, plasma membrane, alpha-tubulin or caveolin-1 labeling. Image collected and cropped by CiteAb from the following publication (//molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-12-84), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Caveolin-1-Antibody-7C8-Immunocytochemistry-Immunofluorescence-NB100-615-img0014.jpg)
![Immunohistochemistry-Frozen: Caveolin-1 Antibody (7C8) [NB100-615] - Immunofluorescence of human adipose tissue. Primary antibody at 1:250. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Caveolin-1-Antibody-7C8-Immunohistochemistry-Frozen-NB100-615-img0015.jpg)
![Flow Cytometry: Caveolin-1 Antibody (7C8) [NB100-615] - An intracellular stain was performed on HeLa cells with Caveolin-1 Antibody (7C8) NB100-615APC (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to allophycocyanin.](http://images.novusbio.com/fullsize/Caveolin-1-Antibody-7C8-Flow-Cytometry-NB100-615-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: Caveolin-1 Antibody (7C8) [NB100-615] - Antibody at 1:200 dilution (ON incubation) on EaHy926 endothelial cell line showing a clear localization in lipid raft/membrane. Photo courtesy of Alberto Davalos, Yale School of Medicine.](http://images.novusbio.com/fullsize/Caveolin-1-Antibody-7C8-Immunocytochemistry-Immunofluorescence-NB100-615-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: Caveolin-1 Antibody (7C8) [NB100-615] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with anti-Caveolin-1 [7C8] conjugated to Alexa Fluor 488 (NB100-615AF488) at 20 ug/mL for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Caveolin-1-Antibody-7C8-Immunocytochemistry-Immunofluorescence-NB100-615-img0013.jpg)
![Flow Cytometry: Caveolin-1 Antibody (7C8) [NB100-615] - Intracellular flow cytometric staining of 1 x 10^6 CHO (A) and HEK-293 (B) cells using Caveolin 1 antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/Caveolin-1-Antibody-7C8-Flow-Cytometry-NB100-615-img0008.jpg)
![Flow Cytometry: Caveolin-1 Antibody (7C8) [NB100-615] - An intracellular stain was performed on HeLa cells with Caveolin-1 Antibody (7C8) NB100-615 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).](http://images.novusbio.com/fullsize/Caveolin-1-Antibody-7C8-Flow-Cytometry-NB100-615-img0011.jpg)
![Western Blot: RelA/NFkB p65 Antibody [NB100-2176] - Human glomerular endothelial cell lysates, time-response treatment with 10ng/ml TNF-alpha. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-Western-Blot-NB100-2176-img0006.jpg "Western Blot: RelA/NFkB p65 Antibody [NB100-2176] - Human glomerular endothelial cell lysates, time-response treatment with 10ng/ml TNF-alpha. This image was submitted via customer Review.")
![Immunohistochemistry-Paraffin: RelA/NFkB p65 Antibody [NB100-2176] - Staining of formalin-fixed, paraffin-embedded human DLBCL showing nuclear expression of NFkB p65 in the tumor cells.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-Immunohistochemistry-Paraffin-NB100-2176-img0004.jpg)
![Western Blot: RelA/NFkB p65 Antibody [NB100-2176] - Analysis of NFkB p65 expression in A431 (A) and HeLa (B) whole cell lysates.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-Western-Blot-NB100-2176-img0005.jpg)
![Immunohistochemistry-Paraffin: Rabbit Polyclonal RelA/NFkB p65 Antibody [NB100-2176] - RelA/NFkB p65 IHC (brown) in the mice liver tissue; bars, 200 μm. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-2176_rabbit-polyclonal-rela-nfkb-p65-antibody-immunohistochemistry-paraffin-1111202410307..jpg)
![Immunocytochemistry/Immunofluorescence: Rabbit Polyclonal RelA/NFkB p65 Antibody [NB100-2176] - Mice hepatocytes stained for RelA/NFkB p65. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-2176_rabbit-polyclonal-rela-nfkb-p65-antibody-immunocytochemistry-immunofluorescence-2511202410544..png)
![Western Blot: TRAILR2/TNFRSF10B Antibody [NB100-56618] - TRAIL R2/TNFRSF10B Antibody [NB100-56618] - Total protein from HL-60, HepG2, HCT-116 and human placenta was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TRAIL R2 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-Western-Blot-NB100-56618-img0005.jpg "Western Blot: TRAILR2/TNFRSF10B Antibody [NB100-56618] - TRAIL R2/TNFRSF10B Antibody [NB100-56618] - Total protein from HL-60, HepG2, HCT-116 and human placenta was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TRAIL R2 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunohistochemistry-Paraffin: TRAILR2/TNFRSF10B Antibody [NB100-56618] - TRAIL R2/TNFRSF10B Antibody [NB100-56618] - Analysis of a formalin fixed paraffin-embedded (FFPE) human brain cerebellum using 1:200 conc. of TRAIL R2/TNFRSF10B antibody on a Bond Rx autostainer (Leica Biosystems). The assay involved 30 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 9.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 15 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Cytoplasmic staining was observed in the Purkinje cell layer.](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-Immunohistochemistry-Paraffin-NB100-56618-img0007.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: TRAILR2/TNFRSF10B Antibody [NB100-56618] - Pharmacodynamic assays for ONC201. IHC analyses of CHOP, TRAILR2/TNFRSF10B, and double-stranded DNA breaks (TUNEL) in baseline and ONC201-treated biopsies for an endometrial cancer patient. The biopsy was done 9.8 months after starting ONC201 treatment (7 days after the most recent ONC201 dose). Image collected and cropped by CiteAb from the following publication (//jitc.biomedcentral.com/articles/10.1186/s40425-019-0599-8) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TRAILR2-TNFRSF10B-Antibody-Immunohistochemistry-NB100-56618-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: TRAIL R2/TNFRSF10B Antibody [NB100-56618] - HepG2 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-TRAIL R2 (H76) at 5ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-Immunocytochemistry-Immunofluorescence-NB100-56618-img0004.jpg)
![Western Blot: TRAILR2/TNFRSF10B Antibody [NB100-56618] - TRAIL R2/TNFRSF10B Antibody [NB100-56618] - Analysis using the Azide Free version of NB100-56618. Detection of 20 ug of whole cell lysates from HL60 cells with anti-TRAIL-R2 at 5 ug/ml.](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-Western-Blot-NB100-56618-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: GAPDH Antibody (13H12) [NBP2-27103] - GAPDH antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red). A dilution of 1:10 was used. Image objective 40x.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Immunocytochemistry-Immunofluorescence-NBP2-27103-img0013.jpg "Immunocytochemistry/Immunofluorescence: GAPDH Antibody (13H12) [NBP2-27103] - GAPDH antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red). A dilution of 1:10 was used. Image objective 40x.")
![Western Blot: GAPDH Antibody (13H12) [NBP2-27103] - WB detection of GAPDH protein (theoretical molecular weight: 36 kDa) in HeLa cells lysate using GAPDH antibody (clone 13H12) in (A) the absence and (B) the presence of immunizing peptide.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Western-Blot-NBP2-27103-img0001.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody (13H12) [NBP2-27103] - IHC-P detection GAPDH protein in a formalin-fixed paraffin-embedded section of human rectal carcinoma tissue using GAPDH antibody (clone 13H12) at 5 ug/ml concentration.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Immunohistochemistry-Paraffin-NBP2-27103-img0011.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody (13H12) [NBP2-27103] - IHC-P detection GAPDH protein in a formalin-fixed paraffin-embedded section of normal human breast tissue using GAPDH antibody (clone 13H12) at 5 ug/ml concentration.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Immunohistochemistry-Paraffin-NBP2-27103-img0008.jpg)
![Western Blot: GAPDH Antibody (13H12) [NBP2-27103] - Characterization of lncR492.(B) Northern blot of lncR494 using increasing amounts of loaded total. Black arrow signifies lncR492-specific signal at approximately 1400 bp. A probe targeting Gapdh mRNA served as the loading control. (D) RT-PCR analysis of lncR492 and Gapdh expression. RNA extract was treated with a 5'-phosphate-dependent exonuclease, resulting in a degradation of f.ex. ribosomal RNA.Citation: Winzi M, Casas Vila N, Paszkowski-Rogacz M, Ding L, Noack S, Theis M, et al. (2018) The long noncoding RNA lncR492 inhibits neural differentiation of murine embryonic stem cells. PLoS ONE 13(1): e0191682. //doi.org/10.1371/journal.pone.0191682](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Western-Blot-NBP2-27103-img0017.jpg)
![Western Blot: GAPDH Antibody (13H12) [NBP2-27103] - Serum from trauma patients induces intrinsic apoptosis resistance by up-regulating AAT expression in neutrophils. AAT protein expression was analyzed in neutrophils after 18 h of culture by western blot analysis. Relative expression was quantified vs. GAPDH expression. One representative blot of five independent experiments is depicted. **p<0.01 (one-way ANOVA with Newman keuls post-hoc test). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0177450), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Western-Blot-NBP2-27103-img0018.jpg)
![Western Blot: GAPDH Antibody (13H12) [NBP2-27103] - WB detection of GAPDH protein (theoretical molecular weight 36 kDa) in lysates of Mouse cell lines (A) NIH 3T3 (B) RAW 264.7 using GAPDH antibody (clone 13H12) at a concentration of 0.25 ug/ml.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Western-Blot-NBP2-27103-img0005.jpg)
![Western Blot: GAPDH Antibody (13H12) [NBP2-27103] - analysis of GAPDH in HeLa and HEK 293 cells (25ug/lane) using anti-GAPDH antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Western-Blot-NBP2-27103-img0014.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody (13H12) [NBP2-27103] - IHC-P detection GAPDH protein in a formalin-fixed paraffin-embedded section of normal human stomach tissue using GAPDH antibody (clone 13H12) at 5 ug/ml concentration.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Immunohistochemistry-Paraffin-NBP2-27103-img0007.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody (13H12) [NBP2-27103] - IHC-P detection GAPDH protein in a formalin-fixed paraffin-embedded section of human colon tissue using GAPDH antibody (clone 13H12) at 5 ug/ml concentration.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Immunohistochemistry-Paraffin-NBP2-27103-img0009.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody (13H12) [NBP2-27103] - IHC-P detection GAPDH protein in a formalin-fixed paraffin-embedded tissue section of human esophageal squamous cell carcinoma (SCC) using GAPDH antibody (clone 13H12) at 5 ug/ml concentration.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Immunohistochemistry-Paraffin-NBP2-27103-img0010.jpg)
![Simple Western: GAPDH Antibody (13H12) [NBP2-27103] - GAPDH/G3PDH Antibody (13H12) [NBP2-27103] - Simple Western lane view shows a specific band for GAPDH in 0.1 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/GAPDH-Antibody-13H12-Simple-Western-NBP2-27103-img0015.jpg)
![Western Blot: GAPDH Antibody (13H12) - BSA Free [NBP2-27103] - Effect of AAT on Mcl-1 phosphorylation, the activity of MAP kinases & caspases.Neutrophils from healthy volunteers (2.5 × 106/ml) were cultured in medium supplemented with patient serum (3 mg protein/ml; 1%) & those containing low levels of AAT (AAT-reduce serum; 1%) in the presence of STS (0.2 μM). After 3 h, the expression of pMcl-1 (A, n = 7), pAkt (B, n = 8) & pERK1/2 (C, n = 10) were analyzed by western blot. Expression levels of the phosphorylated proteins were normalized to that of the unphosphorylated forms. GAPDH was used as loading control. One representative blot is displayed. *p<0.05; **p<0.01; n.s. = not significant. D. After 4 h of incubation the activities of caspase-9 & caspase-3/-7 were quantified. Results are presented as means ± SEM of eight independent experiments. No significant differences were found (one-way ANOVA with Newman keuls post-hoc test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28493974), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27103_mouse-monoclonal-gapdh-antibody-13h12-imgenex-img-6665a-25-31020241612222.jpg)
![Western Blot: GAPDH Antibody (13H12) - BSA Free [NBP2-27103] - Effect of AAT on Mcl-1 phosphorylation, the activity of MAP kinases & caspases.Neutrophils from healthy volunteers (2.5 × 106/ml) were cultured in medium supplemented with patient serum (3 mg protein/ml; 1%) & those containing low levels of AAT (AAT-reduce serum; 1%) in the presence of STS (0.2 μM). After 3 h, the expression of pMcl-1 (A, n = 7), pAkt (B, n = 8) & pERK1/2 (C, n = 10) were analyzed by western blot. Expression levels of the phosphorylated proteins were normalized to that of the unphosphorylated forms. GAPDH was used as loading control. One representative blot is displayed. *p<0.05; **p<0.01; n.s. = not significant. D. After 4 h of incubation the activities of caspase-9 & caspase-3/-7 were quantified. Results are presented as means ± SEM of eight independent experiments. No significant differences were found (one-way ANOVA with Newman keuls post-hoc test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28493974), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27103_mouse-monoclonal-gapdh-antibody-13h12-imgenex-img-6665a-25-310202416114762.jpg)
![Western Blot: GAPDH Antibody (13H12) - BSA Free [NBP2-27103] - Effect of AAT on Mcl-1 phosphorylation, the activity of MAP kinases & caspases.Neutrophils from healthy volunteers (2.5 × 106/ml) were cultured in medium supplemented with patient serum (3 mg protein/ml; 1%) & those containing low levels of AAT (AAT-reduce serum; 1%) in the presence of STS (0.2 μM). After 3 h, the expression of pMcl-1 (A, n = 7), pAkt (B, n = 8) & pERK1/2 (C, n = 10) were analyzed by western blot. Expression levels of the phosphorylated proteins were normalized to that of the unphosphorylated forms. GAPDH was used as loading control. One representative blot is displayed. *p<0.05; **p<0.01; n.s. = not significant. D. After 4 h of incubation the activities of caspase-9 & caspase-3/-7 were quantified. Results are presented as means ± SEM of eight independent experiments. No significant differences were found (one-way ANOVA with Newman keuls post-hoc test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28493974), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27103_mouse-monoclonal-gapdh-antibody-13h12-imgenex-img-6665a-25-310202416121949.jpg)
![Western Blot: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Analysis of Osteopontin expression in U2OS whole cell lysate.](http://images.novusbio.com/fullsize/Osteopontin-OPN-Antibody-1B20-BSA-Free-Western-Blot-NB110-89062-img0007.jpg "Western Blot: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Analysis of Osteopontin expression in U2OS whole cell lysate.")
![Immunocytochemistry/Immunofluorescence: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Osteopontin antibody was tested at 1:50 in U2OS cells with FITC (green). Nuclei and actin were counterstained with Dapi (blue) and Phalloidin (red).](http://images.novusbio.com/fullsize/Osteopontin-OPN-Antibody-1B20-BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-89062-img0008.jpg)
![Immunohistochemistry: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Immunohistological results at 12 weeks for (A) Group I, (B) Group II (C) Group III.The pictures are arranged by staining technique (columns) and by the investigated treatment (rows). Areas that stained positive for osteopontin are indicated by red arrowheads. Image collected and cropped by CiteAb from the following publication (//peerj.com/articles/3513) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Osteopontin-OPN-Antibody-1B20-BSA-Free-Immunohistochemistry-NB110-89062-img0012.jpg)
![Immunohistochemistry: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Osteogenic differentiation in 3D. Immunostaining for osteopontin (OPN) and nuclear DAPI in 3D cultures after 5 weeks. Scale bar = 50 um. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34948393/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Osteopontin-OPN-Antibody-1B20-BSA-Free-Immunohistochemistry-NB110-89062-img0013.jpg)
![Immunohistochemistry: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Analysis of Osteopontin on human lung adenocarcinoma.](http://images.novusbio.com/fullsize/Osteopontin-OPN-Antibody-1B20-BSA-Free-Immunohistochemistry-NB110-89062-img0009.jpg)
![Immunohistochemistry: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Osteopontin in (A) Group I, (B) Group II (C) Group III at 6 weeks. The pictures are arranged by staining technique (columns) and the investigated treatment (rows). Areas that stained positive for osteocalcin and osteopontin are indicated by red arrowheads. NB, new bone; OS, osteoid; FM, fatty marrow. Image collected and cropped by CiteAb from the following publication (//peerj.com/articles/3513) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Osteopontin-OPN-Antibody-1B20-BSA-Free-Immunohistochemistry-NB110-89062-img0011.jpg)
![Simple Western: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Simple Western lane view shows a specific band for Osteopontin in 0.5 mg/ml of Human Breast Cancer lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. * Non-specific interaction with the 230 kDa Simple Western standard may be seen with this antibody](http://images.novusbio.com/fullsize/Osteopontin-OPN-Antibody-1B20-BSA-Free-Simple-Western-NB110-89062-img0010.jpg)
![Immunohistochemistry: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Photomicrographs of immunostaining for osteocalcin & osteopontin in (A) Group I, (B) Group II (C) Group III at 6 weeks.The pictures are arranged by staining technique (columns) & the investigated treatment (rows). Areas that stained positive for osteocalcin & osteopontin are indicated by red arrowheads. NB, new bone; OS, osteoid; FM, fatty marrow. Image collected & cropped by CiteAb from the following publication (//peerj.com/articles/3513), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89062_mouse-monoclonal-osteopontin-opn-antibody-1b20-3102024153560.jpg)
![Immunohistochemistry: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Photomicrographs of immunostaining for osteocalcin & osteopontin in (A) Group I, (B) Group II (C) Group III at 6 weeks.The pictures are arranged by staining technique (columns) & the investigated treatment (rows). Areas that stained positive for osteocalcin & osteopontin are indicated by red arrowheads. NB, new bone; OS, osteoid; FM, fatty marrow. Image collected & cropped by CiteAb from the following publication (//peerj.com/articles/3513), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89062_mouse-monoclonal-osteopontin-opn-antibody-1b20-31020241534321.jpg)
![Western Blot: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Photomicrographs of immunostaining for osteocalcin & osteopontin in (A) Group I, (B) Group II (C) Group III at 6 weeks.The pictures are arranged by staining technique (columns) & the investigated treatment (rows). Areas that stained positive for osteocalcin & osteopontin are indicated by red arrowheads. NB, new bone; OS, osteoid; FM, fatty marrow. Image collected & cropped by CiteAb from the following publication (//peerj.com/articles/3513), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89062_mouse-monoclonal-osteopontin-opn-antibody-1b20-310202415394515.jpg)
